Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
复制标题
DOI：
10.1016/j.jalz.2013.01.002
复制
发表时间：
2013-01-01
影响因子：
14
通讯作者：
Thies, William H.
中科院分区：
文献类型：
--
作者：
Johnson, Keith A.;Minoshima, Satoshi;Thies, William H.
脑淀粉样蛋白β的正电子发射断层扫描（PET）是一种越来越可用的技术，但其在医疗实践中的临床用途需要仔细定义。为了向痴呆症护理从业者、患者和护理人员提供指导，阿尔茨海默病协会和核医学与分子成像学会召集了淀粉样蛋白成像工作组（AIT）。AIT考虑了广泛的特定临床场景，其中淀粉样蛋白PET可能被适当使用。检索了同行评审的已发表文献，以确定与这些情况相关的可用证据，AIT达成了专家意见的共识。尽管尚未获得影响临床结局的经验证据，但已商定了一组特定的适当使用标准（AUC），定义了可使用淀粉样蛋白PET的患者类型和临床情况。适当和不适当的使用都被考虑和制定，并在这里报告和讨论。由于痴呆症护理和淀粉样蛋白PET技术都在积极开发中，这些AUC将需要定期重新评估。未来的研究方向也被概述，包括诊断效用和以患者为中心的结果。(C)2013年，阿尔茨海默氏症协会。All rights reserved.
Positron emission tomography (PET) of brain amyloid beta is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used. Both appropriate and inappropriate uses were considered and formulated, and are reported and discussed here. Because both dementia care and amyloid PET technology are in active development, these AUC will require periodic reassessment. Future research directions are also outlined, including diagnostic utility and patient-centered outcomes. (C) 2013 The Alzheimer's Association. All rights reserved.